CVM — CEL SCI CORP
—
NYSE ·
Health Care ·
Biotechnology ·
CIK 725363 ·
Last close
$1.16
Market Cap
$20.27M
52W High
$2.90
52W Low
$0.89
ADV30
361,987
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -5,326,009 | -5,465,751 | 17,707,274 | 1,890,732 | 10,832,600 |
| Dec 2025 | 0 | — | -5,368,806 | -5,469,446 | 22,894,675 | 6,277,582 | 11,756,021 |
| Sep 2025 | 0 | — | -6,033,332 | -6,100,900 | 28,155,748 | 10,953,460 | 12,198,663 |
| Jun 2025 | 0 | — | -5,488,883 | -5,664,704 | 20,336,199 | 1,792,856 | 13,311,259 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-16,654,679
Investing CF
$-5,155
Financing CF
$16,626,261
CapEx
$-57,862
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-5.04
As of
2026-06-07
Balance + Analyst (yfinance extras)
Retained Earnings
$-550,358,113
Inventory
$281,462
Receivables
—
ST Investments
—
EBIT TTM
$-22,194,972
Pretax Income TTM
$-22,700,801
Interest Exp TTM
$505,829
Analysts
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Sep 2025 | 0 | -24,809,736 | -25,411,055 | 28,155,748 | 12,198,663 | — | -17,119,737 |
| Sep 2024 | 0 | -26,352,474 | -26,920,465 | 26,991,766 | 14,124,683 | — | -18,811,206 |
| Sep 2023 | 0 | -31,476,074 | -32,194,303 | 30,528,250 | 17,313,360 | — | -22,848,561 |
| Sep 2022 | 0 | -36,062,793 | -36,700,681 | 50,523,706 | 18,360,499 | — | -18,240,951 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-6.38
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| JSPR | Jasper Therapeutics, Inc. | $20.96M | $0.63 | — |
| ALGS | Aligos Therapeutics, Inc. | $22.79M | $4.23 | — |
| QNCX | Quince Therapeutics, Inc. | $22.87M | $23.39 | — |
| EVAX | Evaxion A/S | $23.52M | $2.82 | — |
| PLUR | Pluri Inc. | $16.72M | $1.55 | — |
News headlines (Yahoo Finance, 1h cache)
Leading Oncology Journal Accepts For Publication New CEL-SCI Multikine Phase 3 Data Demonstrating Overall Survival Benefit in Underserved Head and Neck Cancer Patients
2026-07-30 12:31 · Yahoo
CEL-SCI to Launch FDA Registration-Enabling Phase 3 Confirmatory Study to Bring Multikine® to Market for Newly Diagnosed Head and Neck Cancer
2026-07-13 12:00 · Yahoo
CVM Stock Sinks In Pre-Market Trading After Announcing Second Equity Raise For Its Cancer Drug In Just Over A Month
2026-06-15 11:12 · Yahoo
Cel-Sci: Fiscal Q1 Earnings Snapshot
2026-02-17 22:14 · Yahoo
CEL-SCI Presentation at LD Micro "Main Event" Available on Tuesday, October 21, 2025
2025-10-20 13:00 · Yahoo
CEL-SCI Corporation to Present at LD Micro "Main Event" Investor Conference
2025-10-10 12:00 · Yahoo
Cel-Sci: Fiscal Q3 Earnings Snapshot
2025-08-14 13:37 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.